Oshima Yuri, Matsuura Hiroyuki, Sakurai Yusuke, Hirai Kaho, Tani Eriko, Yoshimoto Naoki, Minami Kenichi, Yamasaki Fumio, Nishime Mayu, Hirashima Tomonori
Department of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Division of Rehabilitation, Ishikiriseiki Hospital, Osaka, Japan.
Respir Med Case Rep. 2022 Feb 17;36:101609. doi: 10.1016/j.rmcr.2022.101609. eCollection 2022.
Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we started ANA combined with a treatment approach by a multidisciplinary collaboration, including nutritionists and physical therapists. After initiation of ANA, the body weight, appetite, psoas muscle index, and physical functions rapidly improved during chemotherapy. ANA administration combined with a multidisciplinary collaboration approach can be an effective supportive therapy against CCX during chemotherapy.
阿那莫林（ANA）在日本被批准用于治疗癌症恶病质（CCX）。我们报告了一例69岁IVB期肺鳞状细胞癌合并CCX的男性患者，其体重在6个月内下降了13.6%。开始化疗后，他的体重进一步减轻。因此，我们开始使用ANA，并联合包括营养师和物理治疗师在内的多学科协作治疗方法。开始使用ANA后，患者在化疗期间的体重、食欲、腰大肌指数和身体功能迅速改善。ANA给药联合多学科协作方法可成为化疗期间对抗CCX的有效支持疗法。
